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Abstract
Background/objectives This post hoc analysis explores the relationship between residual oedema exposure after ranibizumab treatment initiation and long-term visual acuity outcome in eyes with centre-involved diabetic macular oedema (DMO).
Subjects/methods Eyes randomised to the ranibizumab + prompt or deferred laser treatment arms in the Protocol I trial and
with observed central retinal thickness (CRT) readings at baseline and ≥1 follow-up visits (n = 367) were stratiﬁed by 1)
oedema duration (number of study visits with CRT ≥ 250 µm during the ﬁrst 52 weeks of ranibizumab treatment); and 2)
oedema extent (amount of excess CRT [≥ 250 µm] at each study visit, averaged over the ﬁrst 52 weeks). Associations
between measures of residual oedema and best-corrected visual acuity (BCVA) were assessed in multiple regression
analyses.
Results Oedema duration and oedema extent during the ﬁrst 52 weeks of ranibizumab treatment showed signiﬁcant negative
associations with BCVA improvement at weeks 52, 104 and 156. Eyes with the most persistent oedema gained (mean) 4.4
(95% CI 0.1─8.7) fewer Early Treatment Diabetic Retinopathy Study (ETDRS) letters at week 156 than eyes with the least
persistent oedema (P = 0.044). Eyes with the greatest amount of oedema gained (mean) 9.3 (95% CI 4.0─14.5) fewer
ETDRS letters at week 156 than eyes with the least amount of oedema (P < 0.001).
Conclusions Macular oedema exposure over the ﬁrst 52 weeks of ranibizumab treatment is a negative prognostic factor for
long-term visual acuity improvement in centre-involved DMO.

Introduction
Intravitreal vascular endothelial growth factor-A antagonists
(anti-VEGF agents) are currently regarded as appropriate
ﬁrst-line therapy for most patients with centre-involved
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diabetic macular oedema (DMO), resulting in visual acuity
loss [1]. Randomised clinical trials indicate that these agents
are more effective than laser photocoagulation in reducing
macular thickness and improving visual acuity in eyes with
centre-involved DMO [2–4]. However, despite the intensive
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treatment schedules employed in clinical trials, anatomic and
visual responses to anti-VEGF therapy are often incomplete,
with ~20–65% of eyes demonstrating persistent retinal
thickening [2, 5–7] and ~30–65% of eyes failing to achieve
≥10-letter improvement in best-corrected visual acuity
(BCVA) [2, 3, 5, 8–11] after 1 or 2 years of treatment.
The reasons for inter-subject variation in response to antiVEGF therapy in DMO are incompletely understood, with
polymorphisms in the VEGF gene [12], differences in the
VEGF gene expression [13], disease phenotype [14], glycaemic control [15], macular ischaemia [16], oedema chronicity [17, 18], subfoveal choroidal thickness [19] and foveal
atrophy [17], variously implicated as possible contributory
factors. A post hoc analysis indicating relatively limited visual
acuity improvement in eyes receiving deferred as opposed to
prompt ranibizumab treatment in the RISE and RIDE clinical
trials suggests that chronic macular oedema might reduce the
capacity for vision gain in DMO [20]. The disruption of retinal
architecture that accompanies DMO [21] may result in retinal
glial proliferation, neuronal cell loss and compromised visual
function, persisting in some cases even after oedema resolution [22–26]. The published literature is, however, inconsistent
regarding the relationship between the anatomic and functional responses to laser photocoagulation [27], corticosteroid
[14] and anti-VEGF [18, 28, 29] therapy in DMO.
Early identiﬁcation of patients who are unlikely to beneﬁt
from continuation of anti-VEGF therapy would allow alternative, potentially more effective, disease management strategies to be considered at an earlier stage in the disease
process. The Early Anti-VEGF Response and Long-term
Efﬁcacy programme, a series of post hoc analyses of data from
the Diabetic Retinopathy Clinical Research Network’s Protocol I trial [5], one of the largest published studies of ranibizumab in DMO, was initiated to explore the relationship
between early and long-term anti-VEGF treatment outcomes.
Analyses to date have demonstrated a signiﬁcant association
between early (12-week) and long-term (1- to 3-year) BCVA
improvement with ranibizumab [30], but an apparent dissociation between early reduction in macular thickness and
long-term BCVA improvement [31]. Given that the use of
anti-VEGF treatment in clinical practice is based in large part
on optical coherence tomography changes, the present analysis
explores the anatomic–functional relationship further by
assessing macular thickness over the course of ranibizumab
treatment rather than at a single time point.

Methods
Protocol I study—an overview
Protocol I was a prospective Phase III randomised clinical
trial (ClinicalTrials.gov identiﬁer NCT00445003) that
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compared intravitreal ranibizumab 0.5 mg + prompt (within
3–10 days) or deferred (after ≥24 weeks) laser versus sham
intravitreal injection + prompt laser versus intravitreal
triamcinolone 4 mg + prompt laser in 691 patients
(854 study eyes) with centre-involved DMO. The study
protocol was approved by multiple institutional review
boards, and all patients provided their written informed
consent prior to study participation. The study methodology
is detailed elsewhere [5]. For study inclusion, patients were
required to have a baseline BCVA of 78 to 24 Early
Treatment Diabetic Retinopathy Study (ETDRS) letters
(approximate Snellen equivalent 20/32‒20/320), and central
subﬁeld retinal thickness (CRT) of ≥250 µm, as determined
by time-domain OCT (Stratus, Carl Zeiss Meditec Inc.,
Dublin, CA, USA). Intravitreal injections were performed
every 4 weeks for the ﬁrst 12 weeks, and as needed thereafter; the frequency of laser retreatment was governed by
the extent of central macular oedema. BCVA and CRT
measurements were performed every 4 weeks for the ﬁrst
52 weeks and every 4–16 weeks thereafter. Study ﬁndings
at 1 and 2 years demonstrated an efﬁcacy advantage in the
ranibizumab treatment arms [5, 32], and patients in the
sham injection and intravitreal triamcinolone treatment arms
were offered the option of switching to open-label ranibizumab treatment for the third year [33]. Follow-up ﬁndings
for eyes randomised to ranibizumab plus prompt or deferred
laser treatment indicated that the vision gains achieved
during the ﬁrst 2 years of treatment were largely maintained
at 3 [33] and 5 years [34].

Anatomic and visual response analysis
This analysis is based on 3-year follow-up data from Protocol I study eyes that were randomised to ranibizumab plus
prompt or deferred laser treatment, and in addition, provided an observed CRT reading at baseline and at ≥1
follow-up visits. Pooled study eyes from the two ranibizumab treatment arms were independently stratiﬁed according
to 1) duration of oedema following initiation of ranibizumab, as deﬁned by the cumulative number of study visits
(sequential or nonsequential) with CRT ≥250 µm during the
ﬁrst 52 weeks of treatment; and 2) extent of oedema following initiation of ranibizumab, as deﬁned by the amount
of oedema (CRT ≥250 µm) at each study visit, averaged
over the ﬁrst 52 weeks of treatment. The amount of oedema
at each visit was quantiﬁed as the observed CRT minus
250 μm for eyes with CRT ≥250 μm, and as 0 μm for eyes
with CRT < 250 μm. Based on their stratiﬁcation by duration of oedema, study eyes were categorised as Cohort 1:
0–3 visits, Cohort 2: 4–7 visits, Cohort 3: 8–11 visits and
Cohort 4: 12–14 visits over the ﬁrst 52 weeks (study visits
were scheduled every 4 weeks for the ﬁrst 52 weeks of
ranibizumab treatment; accordingly, the maximum possible
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number of visits during this period was 14). Independently,
based on their stratiﬁcation by extent of oedema, study eyes
were categorised as Quartile 1: percentiles 0–25, Quartile 2:
percentiles 26–50, Quartile 3: percentiles 51–75 and
Quartile 4: percentiles 76–100 of the average amount of
oedema over the ﬁrst 52 weeks.

Statistical analyses were performed with SAS versions 9.3
and 9.4 (SAS Inc., Cary, NC, USA). A P value of <0.05
was considered statistically signiﬁcant.

Persistence of macular oedema into the second year
of ranibizumab treatment

In total, 375 eyes were assigned to the ranibizumab +
prompt or deferred laser treatment arms in the Protocol I
trial; of these, 367 eyes were eligible for inclusion in this
analysis.

Persistence of macular oedema into the second year of
ranibizumab treatment was assessed in terms of 1) the
cumulative number of study visits (sequential or nonsequential) with CRT ≥250 µm during weeks 52–104 (for
cohorts categorised according to the duration of oedema
over the ﬁrst 52 weeks of treatment), and 2) the average
amount of oedema (CRT ≥250 µm) during weeks 52–104
(for quartiles categorised according to the average extent of
oedema over the ﬁrst 52 weeks of treatment).

Relationship between duration and extent of
oedema and visual acuity outcome
To evaluate the relationship between oedema duration/
extent during the ﬁrst 52 weeks of ranibizumab therapy and
long-term visual acuity outcome, BCVA responses (mean
change from baseline in BCVA; proportion of study eyes
with BCVA improvement ≥10 ETDRS letters) at weeks 52,
104, and 156 were compared across Cohorts 1–4 (duration)
and Quartiles 1–4 (extent). Any missing CRT and BCVA
readings at the relevant time points—whether due to missed
or omitted follow-up visits—were imputed using the lastobservation-carried-forward method. Multiple linear and
logistic regression models incorporating covariates for
baseline characteristics (age, baseline BCVA, baseline CRT
and prior DMO treatment [Yes/No]) and treatment intensity
(cumulative number of ranibizumab injections and laser
procedures) were used to explore the association between
oedema duration/extent (the primary explanatory covariate)
and long-term BCVA response.

Statistical analysis
Baseline characteristics and visual acuity outcomes were
compared across oedema categories using KruskalWallis
one-way analysis of variance (continuous variables) and
Pearson"s chi-square test (categorical variables). Pairwise
comparisons were performed with the Student’s t-test
(continuous variables) and Pearson’s chi-square test (categorical variables). Correlations between oedema duration/
extent in years 1 and 2 were assessed using Pearson’s
correlation. Probability values in the linear and logistic
regression analyses were determined using Student’s t-test.

Results

Duration of oedema analysis
Of the analysis population, 23.2% of eyes (n = 85) had
0–3 study visits, 24.5% (n = 90) had 4–7 study visits,
19.1% (n = 70) had 8–11 study visits and 33.2% (n = 122)
had 12–14 study visits with CRT ≥ 250 µm during the ﬁrst
52 weeks of ranibizumab treatment (Cohorts 1, 2, 3 and 4,
respectively).
Persistence of macular oedema into year 2 of treatment
The pattern of study visits with macular thickening during
the ﬁrst year of ranibizumab treatment was largely replicated during the second year. Eyes with the most persistent
(Cohort 4) and least persistent (Cohort 1) macular oedema
during the ﬁrst 52 weeks generally displayed the most
persistent and least persistent oedema, respectively, during
the second 52 weeks. The cumulative number of study visits
with CRT ≥ 250 µm in the ﬁrst and second 52-week periods
showed a signiﬁcant correlation (Pearson correlation coefﬁcient = 0.742; P < 0.001).
Relationship between duration of oedema and long-term
visual acuity outcome
In unadjusted analyses, eyes with more persistent macular
oedema during the ﬁrst 52 weeks of ranibizumab treatment
showed less long-term BCVA improvement than eyes with
less persistent macular oedema. The mean (± standard
deviation [SD]) BCVA improvement from baseline (Cohort
4 versus Cohort 1) was 6.3 (± 14.3) versus 11.5 (± 8.9)
ETDRS letters (P = 0.001) at week 52, 5.9 (± 17.0) versus
10.5 (± 9.3) ETDRS letters (P = 0.013) at week 104 and 6.9
(± 15.6) versus 9.5 (± 12.7) ETDRS letters (P = 0.186) at
week 156 (Fig. 1).
Inter-cohort comparisons revealed signiﬁcant differences
in baseline CRT, prior DMO treatment and on-study treatment intensity between eyes with more persistent versus
less persistent macular oedema during the ﬁrst 52 weeks of
ranibizumab therapy (Table 1). After adjusting for age,
baseline BCVA and CRT, prior DMO treatment and the
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BCVA Mean Change from Baseline at
Week 52

A
16

P value across cohorts: 0.006
P value for C1 vs. C4: 0.001

14
12
10
8

11.5
9.7

6

10.2

4
6.3

2
0
C1: 0–3 visits
(N=85)

C2: 4–7 visits
(N=90)

C3: 8–11 visits
(N=70)

C4: 12–14 visits
(N=122)

Visits with CRT ≥ 250 μm at Week 52

Mean BCVA Change from Baseline at
Week 104

B

P value across cohorts: 0.024
P value for C1 vs. C4: 0.013

14
12
10
8
6

10.5

10.0

10.6

4
2

5.9

0
C1: 0–3 visits
(N=85)

C2: 4–7 visits
(N=90)

C3: 8–11 visits
(N=70)

C4: 12–14 visits
(N=122)

Visits with CRT ≥ 250 μm at Week 104

Mean BCVA Change from Baseline at
Week 156

C

P value across cohorts: 0.510
P value for C1 vs. C4: 0.186

14
12
10
8
6

9.5

4

8.6

9.3
6.9

2
0
Q1: 0–3 visits
(N=85)

Q2: 4–7 visits
(N=90)

Q3: 8–11 visits
(N=70)

Q4:12–14 visits
(N=122)

Visits with CRT ≥250 μm at Week 156

Fig. 1 Mean (95% CI) change from baseline in BCVA at a week 52,
b week 104 and c week 156 among study eyes categorised by the
cumulative number of study visits with CRT ≥ 250 µm during the ﬁrst

52 weeks of ranibizumab treatment (N = 367). BCVA best-corrected
visual acuity, C cohort, CRT central subﬁeld retinal thickness,
Q quartile

cumulative number of on-study laser procedures and ranibizumab injections (‘the standard covariates’), multiple
linear regression analysis demonstrated a signiﬁcant negative association between oedema duration during the ﬁrst

52 weeks and BCVA improvement (from baseline) at 52,
104 and 156 weeks. Compared with Cohort 1 (least persistent macular oedema), Cohort 4 (most persistent oedema)
was estimated to have gained, on average, 4.4 (95%
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Table 1 Baseline characteristics
and treatment intensity of study
eyes categorised by duration of
oedema (cumulative number of
study visits with CRT ≥ 250 µm)
during the ﬁrst 52 weeks of
ranibizumab treatment
(N = 367)
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Cumulative number of visits with CRT ≥250 µm during the
ﬁrst 52 weeks

Characteristic

Cohort 1 ≤ 3 Cohort 2 Cohort 3
Cohort 4
P valuea
visits
4–7 visits 8–11 visits 12–14 visits
(n = 85)
(n = 90) (n = 70)
(n = 122)
Mean age, years

61.3

62.6

63.9

63.3

0.451

Male, n (%)

40 (47.1)

51 (56.7)

42 (60.0)

74 (60.7)

0.232

Mean baseline BCVA, ETDRS letters

64.7

62.4

60.4

63.1

0.223

Mean baseline CRT, µm

339

415

420

439

<0.001

Prior DMO therapy, n (%)

41 (48.2)

57 (63.3)

48 (68.6)

77 (63.1)

Cumulative no. of ranibizumab injections
at week 52, mean

5.8

8.0

9.2

10.1

<0.001

Cumulative no. of ranibizumab injections
at week 104, mean

6.6

10.9

12.6

14.2

<0.001

Cumulative no. of ranibizumab injections
at week 156, mean

7.1

12.9

15.4

16.8

<0.001

Cumulative no. of laser procedures at week 0.8
52, mean

1.1

1.4

1.7

<0.001

Cumulative no. of laser procedures at week 0.9
104, mean

1.5

2.0

2.3

<0.001

Cumulative no. of laser procedures at week 1.1
156, mean

1.7

2.1

2.6

<0.001

0.048

BCVA best-corrected visual acuity, CRT central subﬁeld retinal thickness, DMO diabetic macular oedema,
ETDRS Early Treatment Diabetic Retinopathy Study
a

Comparison across all four cohorts, using Kruskal–Wallis one-way analysis of variance for continuous
variables and Pearson’s chi-square test for categorical variables

conﬁdence interval [CI] 1.0–7.9) fewer ETDRS letters at
week 52 (P = 0.012), 6.2 (95% CI 2.1–10.2) fewer ETDRS
letters at week 104 (P = 0.003) and 4.4 (95% CI 0.1–8.7)
fewer ETDRS letters at week 156 (P = 0.044) (Table 2).
Multiple logistic regression analysis with adjustment for
the standard covariates indicated a signiﬁcant negative association between duration of oedema during the ﬁrst 52 weeks
of ranibizumab treatment and categorical BCVA response
(proportion of eyes with ≥10-letter improvement) at 52, 104
and 156 weeks. Compared with Cohort 1, eyes in the two
categories with the most persistent macular oedema (Cohorts
3 and 4) were signiﬁcantly less likely to achieve ≥10-letter
improvement in BCVA at weeks 52, 104, and 156 (Table 2).

Persistence of macular oedema into year 2 of treatment
The pattern of distribution of oedema between study eyes
during the ﬁrst year of ranibizumab treatment was generally
maintained during the second year. Eyes having the highest
(Quartile 4) and lowest (Quartile 1) average amount of
oedema during the ﬁrst 52 weeks of ranibizumab treatment
predominantly showed the highest and lowest average
amounts, respectively, of oedema during the second
52 weeks. The average amount of oedema was signiﬁcantly
correlated between the ﬁrst and second 52-week periods
(Pearson correlation coefﬁcient = 0.673; P < 0.001).

Extent of oedema analysis

Relationship between oedema severity and long-term
visual acuity outcome

Among individual study eyes, the average amount of
oedema (based on a CRT threshold of 250 μm) over the ﬁrst
52 weeks of ranibizumab treatment ranged from 0 to
287 μm. Stratiﬁcation of eyes by percentile of the average
amount of oedema yielded the following cohorts: Quartile 1:
average excess CRT 0–9 μm (mean average 4 μm) (n = 92);
Quartile 2: average excess CRT 9–29 μm (mean average
18 μm) (n = 92); Quartile 3: average excess CRT 29–74 μm
(mean average 47 μm) (n = 92); Quartile 4: average excess
CRT 75–287 μm (mean average 129 μm) (n = 91).

Unadjusted analyses indicated a tendency for eyes with
higher levels of oedema during the ﬁrst 52 weeks of ranibizumab treatment to show less pronounced long-term
BCVA improvement than eyes with lower levels of oedema.
The mean (±SD) BCVA improvement from baseline
(Quartile 4 vs. Quartile 1) was 7.8 (±14.7) versus 10.5
(±8.1) ETDRS letters (P = 0.124) at week 52, 7.9 (±17.4)
versus 9.7 (±8.8) ETDRS letters (P = 0.401) at week 104
and 8.2 (±15.2) versus 9.1 (±11.1) ETDRS letters (P =
0.636) at week 156 (Fig. 2).
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Table 2 Estimated differences in
long-term BCVA outcomes
among study eyes categorised
by 1) duration of oedema
(cumulative number of study
visits with CRT ≥250 µm) and 2)
average extent of oedema
(CRT ≥250 µm) over the ﬁrst
52 weeks of ranibizumab
treatment, after adjustment for
potential confounders

Time

P value Odds ratio (95% CI) of achieving
Estimated difference (95% CI) in
≥10-letter BCVA improvementa
BCVA improvement (ETDRS letters)a
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P value

Study eyes categorised by duration of oedema (cumulative number of study visits with CRT ≥250 µm) over
the ﬁrst 52 weeks of ranibizumab treatment
Week 52
Cohort 2

−1.9 (−5.1 to 1.4)

0.253

0.58 (0.29–1.16)

0.124

Cohort 3

−1.3 (−4.9 to 2.2)

0.461

0.45 (0.21–0.99)

0.047

Cohort 4

−4.4 (−7.9 to −1.0)

0.012

0.31 (0.15–0.67)

0.003

Week 104
Cohort 2

−2.1 (−5.9 to 1.8)

0.289

0.47 (0.23–0.94)

0.032

Cohort 3

−1.7 (−6.0 to 2.5)

0.417

0.45 (0.21–0.96)

0.040

Cohort 4

−6.2 (−10.2 to −2.1)

0.003

0.23 (0.11–0.50)

<0.001

−2.6 (−6.7 to 1.5)

0.216

0.37 (0.18–0.74)

0.005

Week 156
Cohort 2
Cohort 3

−2.5 (−7.1 to 2.1)

0.280

0.41 (0.19–0.89)

0.024

Cohort 4

−4.4 (−8.7 to −0.1)

0.044

0.31 (0.15–0.63)

0.001

Study eyes categorised by average amount of excess oedema (CRT > 250 μm) over the ﬁrst 52 weeks of
ranibizumab treatment
Week 52
Quartile 2 −1.7 (−4.8 to 1.5)

0.297

0.51 (0.26–1.00)

0.051

Quartile 3 −5.3 (−8.9 to −1.8)

0.003

0.39 (0.18–0.84)

0.016

Quartile 4 −6.9 (−11.1 to −2.7)

0.001

0.28 (0.11–0.71)

0.007

Week 104
Quartile 2 −3.1 (−6.8 to 0.7)

0.107

0.42 (0.21–0.83)

0.012

Quartile 3 −6.0 (−10.1 to −1.9)

0.005

0.28 (0.13–0.61)

0.001

Quartile 4 −9.8 (−14.7 to −4.8)

<0.001

0.21 (0.08–0.54)

0.001

Week 156
Quartile 2 −3.6 (−7.6 to 0.4)

0.075

0.40 (0.20–0.78)

0.007

Quartile 3 −7.0 (−11.4 to −2.6)

0.002

0.21 (0.10–0.46)

<0.001

Quartile 4 −9.3 (−14.5 to −4.0)

<0.001

0.13 (0.05–0.34)

<0.001

BCVA best-corrected visual acuity, CI conﬁdence interval, CRT central retinal thickness, DMO diabetic
macular oedema, ETDRS Early Treatment Diabetic Retinopathy Study
a
Estimated differences and odds ratios are expressed relative to Cohort/Quartile 1, with adjustment for age,
baseline BCVA, baseline CRT, prior DMO treatment and cumulative number of ranibizumab injections and
laser procedures

Signiﬁcant differences in baseline BCVA and CRT,
and on-study treatment intensity were noted between eyes
with higher and lower average amounts of macular
oedema during the ﬁrst 52 weeks of ranibizumab therapy
(Table 3). Multiple linear regression analysis with
adjustment for the standard covariates demonstrated a
signiﬁcant negative association between average amount
of macular oedema during the ﬁrst 52 weeks of ranibizumab treatment and BCVA improvement at 52, 104 and
156 weeks. Compared with eyes with the lowest average
amount of oedema (Quartile 1), eyes with the highest
amount of oedema (Quartile 4) were estimated to have
gained, on average, 6.9 (95% CI 2.7–11.1) fewer ETDRS
letters at week 52 (P = 0.001), 9.8 (95% CI 4.8–14.7)
fewer ETDRS letters at week 104 (P < 0.001) and 9.3

(95% CI 4.0–14.5) fewer ETDRS letters at week 156 (P <
0.001) (Table 2).
A signiﬁcant negative association was noted between the
average amount of oedema during the ﬁrst 52 weeks of
ranibizumab treatment and the likelihood of achieving a
≥10-letter improvement in BCVA at 52, 104 and
156 weeks. Compared with Quartile 1, Quartiles 3 and 4
were signiﬁcantly less likely to show a ≥10-letter
improvement in BCVA at weeks 52, 104 and 156 (Table 2).

Discussion
This analysis of the Protocol I study data suggests that
approximately one-quarter of eyes receiving intravitreal
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BCVA Mean Change from Baseline at
Week 52

A

14

P value across quartiles = 0.158
P value for Q1 vs. Q4 = 0.124

12
10
8

10.5

6

10.3
7.7

4

7.8

2
0

Q1: excess CRT
0–9 µm
(N=92)

Q2: excess CRT
9–29 µm
(N=92)

Q3: excess CRT
29–74 µm
(N=92)

Q4: excess CRT
75–287 µm
(N=91)

Quartiles of average amount of excess oedema (CRT ≥ 250 μm)
over first 52 weeks

BCVA Mean Change from Baseline at
Week 104

B
14

P value across quartiles = 0.804
P value for Q1 vs. Q4 = 0.401

12
10
8
6

9.7

9.4
8.6

4

7.9

2
0

Q1: excess CRT
0–9 µm
(N=92)

Q2: excess CRT
Q3: excess CRT
9–29 µm
29–74 µm
(N=92)
(N=92)
Quartiles of average amount of excess oedema (CRT ≥ 250 μm)
over first 52 weeks

Q4: excess CRT
75–287 µm
(N=91)

BCVA Mean Change from Baseline at
Week 156

C
14

P value across quartiles = 0.840
P value for Q1 vs. Q4 = 0.636

12
10
8
6

9.1
8.8

4

7.4

2
0

Q1: excess CRT
0–9 µm
(N=92)

Q3: excess CRT
Q2: excess CRT
29–74 µm
9–29 µm
(N=92)
(N=92)
Quartiles of average amount of excess oedema (CRT ≥ 250 μm)
over first 52 weeks

Fig. 2 Mean (95% CI) change from baseline in BCVA at a week 52,
b week 104 and c week 156 among study eyes categorised by the
average amount of excess oedema (CRT ≥250 µm) during the ﬁrst

8.2

Q4: excess CRT
75–287 µm
(N=91)

52 weeks of ranibizumab treatment (N = 367). BCVA best-corrected
visual acuity, CRT central subﬁeld retinal thickness, Q quartile
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Table 3 Baseline characteristics
and treatment intensity of study
eyes categorised by extent of
oedema (average amount of
oedema [CRT ≥250 µm]) during
the ﬁrst 52 weeks of
ranibizumab treatment
(N = 367)
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Average amount of oedema (CRT ≥250 µm) during the
ﬁrst 52 weeks

Characteristic

Quartile 1 Quartile 2 Quartile 3 Quartile 4 P valuea
0–9 µm
9–29 µm 29–74 µm 75–287 µm
(n = 92)
(n = 92)
(n = 92)
(n = 91)
Mean age, years

62.0

63.1

63.7

62.4

0.660

Male, n (%)

46 (50.0)

50 (54.3)

54 (58.7)

57 (62.6)

0.344

Mean baseline BCVA, ETDRS letters

66.6

62.9

61.9

59.7

0.001

Mean baseline CRT, µm

307

380

433

506

<0.001

Prior DMO therapy, n (%)

48 (52.2)

58 (63.0)

58 (63.0)

59 (64.8)

Cumulative no. of ranibizumab injections at
week 52, mean

6.0

7.9

9.3

10.5

<0.001

Cumulative no. of ranibizumab injections at
week 104, mean

7.0

10.3

12.5

15.7

<0.001

Cumulative no. of ranibizumab injections at
week 156, mean

7.8

11.8

14.9

18.9

<0.001

Cumulative no. of laser procedures at week
52, mean

0.9

1.3

1.3

1.7

0.002

Cumulative no. of laser procedures at week
104, mean

1.0

1.8

1.8

2.3

<0.001

Cumulative no. of laser procedures at week
156, mean

1.2

1.9

2.0

2.7

<0.001

0.275

BCVA best-corrected visual acuity, CRT central subﬁeld retinal thickness, DMO diabetic macular oedema,
ETDRS Early Treatment Diabetic Retinopathy Study
a

Comparison across all four cohorts, using Kruskal–Wallis one-way analysis of variance for continuous
variables and Pearson’s chi-square test for categorical variables

ranibizumab for centre-involved DMO achieved nearpermanent resolution of macular oedema (as signiﬁed by
≤3 of a total of 14 study visits with CRT ≥250 µm during the
ﬁrst 52 weeks of treatment). In contrast, for one-third of
ranibizumab-treated eyes, macular oedema persisted uninterrupted throughout most of the ﬁrst 52 weeks (as signiﬁed
by 12–14 of 14 study visits with CRT ≥250 µm). Moreover,
of those eyes that showed chronic persistent oedema during
the ﬁrst year of ranibizumab treatment, approximately twothirds continued to experience uninterrupted or nearuninterrupted oedema during the second year. These ﬁndings are consistent with those of an earlier exploration of
DMO evolution under long-term ranibizumab treatment,
which was also based on a subgroup analysis of the Protocol I study data [18]. Among study eyes with persistent
oedema after 6 months of ranibizumab treatment (n = 117),
the cumulative probability of chronic persistent DMO was
81% at 12 months, 56% at 24 months, and 40% at
36 months [18]. Thus, even with a sustained, as-needed
retreatment regimen and close patient follow-up, resolution
of chronic oedema is a slow, gradual and often incomplete
process.
Unadjusted analysis of the Protocol I study data suggests
that long-term vision outcome with ranibizumab is more
closely inﬂuenced by the duration (persistence) than by the
severity of macular oedema during the initial 52 weeks of

treatment. However, after adjusting for potential confounders, both oedema duration and oedema severity
showed signiﬁcant negative association with long-term (1to 3-year) visual acuity outcomes. Eyes with the most persistent macular oedema over the ﬁrst 52 weeks of treatment
gained, on average, 4.4 fewer ETDRS letters at week 156
than eyes with the least persistent macular oedema. Likewise, eyes with the greatest average amount of macular
oedema over the ﬁrst 52 weeks of treatment gained 9.3
fewer ETDRS letters at week 156 than eyes with the least
amount of macular oedema. Hence, the improvement in
visual acuity obtained with long-term ranibizumab treatment appears to be negatively associated with the overall
burden (intensity and persistence) of exposure to oedema.
A unique feature of the current analysis is that anatomic
response to ranibizumab was assessed longitudinally over
the ﬁrst 52 weeks of treatment rather than at a single time
point. This is in contrast to previous Early Anti-VEGF
Response and Long-term Efﬁcacy programme analyses,
which typically assessed anatomic response to ranibizumab
at week 12 of treatment (i.e., after the ﬁrst three monthly
intravitreal injections) and failed to demonstrate a signiﬁcant association between early CRT reduction and longterm BCVA improvement [31]. Similarly, retrospective
analyses of the RISE/RIDE study data suggest a dissociation between early anatomic response to ranibizumab after
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the third monthly intravitreal injection and long-term
(2-year) visual acuity outcome in DMO [29]. Accordingly, reduction of oedema exposure (chronicity and/or
severity) over the ﬁrst 52 weeks of ranibizumab treatment
would appear to be of greater prognostic importance for
long-term visual acuity improvement than acute reduction
of macular thickness. In support of this proposition, an
independent post hoc analysis of Protocol I study data
indicated that early (week 16) and sustained (weeks 32 and
52) CRT reduction (≥20%) was associated with a better
visual acuity outcome at week 52 than early but unsustained
CRT reduction [28]. Moreover, a subsequent exploratory
analysis of the Protocol I study data indicated that the longterm (3-year) visual acuity response of eyes with chronic
persistent oedema through 3 years was signiﬁcantly worse
than that of eyes with less persistent oedema [18].
The presence of chronic oedema may signify a transition
from the acute inﬂammation and vascular dysfunction
characteristic of early-stage DMO to the chronic inﬂammation and neuronal damage of later-stage disease [14]. It is
suggested that as the pathophysiology of DMO evolves, so
too may the retinal response to anti-VEGF treatment [14].
Persistent and/or recurrent macular oedema has been
implicated as a possible contributory factor to poor visual
acuity outcome in ranibizumab-treated eyes [17, 18, 20].
Consequently, delay in initiating anti-VEGF treatment may
potentially reduce the scope for vision improvement [20].
Consistent with this hypothesis, a post hoc analysis of the
RISE/RIDE studies reported that BCVA improvement in
eyes randomised to 2 years of sham intravitreal injection and
then switched to monthly ranibizumab 0.5 mg treatment for
the third year (mean 2.8 ETDRS letters) was substantially
less than that achieved after the ﬁrst year of ranibizumab
treatment in eyes randomised to monthly ranibizumab 0.3 or
0.5 mg from the outset (mean 10.6 and 11.1 ETDRS letters,
respectively) [20]. Accordingly, retention of residual ﬂuid on
the macula would appear to have a detrimental effect over
time, limiting the potential visual beneﬁt that might be
achieved with anti-VEGF therapy.
This analysis has a number of strengths, including its
large sample size, extended treatment duration, and use of
data based on a randomised study design, and a standardised retreatment protocol and OCT methodology.
Although the axial resolution and retinal layer delineation
provided by time-domain OCT scanning (the modality
employed in the Protocol I study) are inferior to those of
the spectral-domain OCT devices currently in use [35],
time-domain OCT measurements are nevertheless reproducible and correlate with other morphometric parameters
of macular anatomy in DMO [36]. Persistence of the
association between oedema duration/intensity and visual
outcome after raising the speciﬁed threshold for macular
oedema to CRT ≥300 µm in a sensitivity analysis (results
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not shown) attests to the robustness of the study ﬁndings.
Limitations of the analysis include its retrospective design,
the imputation of missing data (last-observation-carriedforward method) and the absence of information on other
factors that might inﬂuence DMO progression and response
to anti-VEGF therapy, such as disease duration, subtype
and morphologic pattern, severity of diabetic retinopathy
and macular ischaemia and level of glycaemic control
[28, 37–40].
In summary, the current analysis re-examines the relationship between anatomic and functional response to
ranibizumab and demonstrates that greater exposure to
macular oedema over the ﬁrst year of treatment is associated
with signiﬁcantly worse visual acuity outcome. Oedema
exposure, as measured by the duration of macular oedema
or by the average amount of excess macular thickness over
the ﬁrst 52 weeks of treatment, was shown to be a negative
prognostic factor for long-term (3-year) visual acuity
improvement in ranibizumab-treated eyes with centreinvolved DMO. Assessment of anatomic response over
multiple time points suggests that the structure–function
relationship revealed with ranibizumab in DMO is reasonably robust. For patients with persistent macular oedema
during anti-VEGF therapy, further research is required to
assess the beneﬁts of early introduction of additional or
alternative disease management strategies and their optimal
timing. The recent DRCR.net Protocol U study, which
evaluated the effect of adjunctive intravitreal dexamethasone in ranibizumab-treated eyes with persistent
centre-involved DMO following at least 6 months of antiVEGF therapy [41], provides an initial guideline for when
one might consider changing therapy, and represents an
important step in this direction.

Summary
What was known before
●

●

●

There is marked inter-subject variability in anatomical
and functional responses to anti-VEGF therapy in DMO.
Indirect evidence from the RISE and RIDE trials
suggests that persistence of macular oedema during
anti-VEGF therapy might limit subsequent vision gain.
Post hoc analysis of Protocol I study data failed to show
an association between the reduction in macular
thickness at week 12 and long-term vision improvement
in ranibizumab-treated eyes with centre-involved DMO.

What this study adds
●

Based on OCT assessments over multiple time points,
this analysis of Protocol I study data demonstrates that

Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in. . .

residual oedema exposure (intensity and duration) over
the ﬁrst 12 months of treatment is a negative prognostic
factor for long-term vision outcome in ranibizumabtreated eyes with centre-involved DMO.
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